• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Liraglutide for the prevention of major adverse cardiovascular events in diabetic patients.
Authors: Madsbad S Abstract INTRODUCTION: The GLP-1 receptor agonist (GLP-1 RA) liraglutide has a half-life of approximately 13 h and is suitable for subcutaneous administration once daily. The use of liraglutide in people with type 2 diabetes has become popular because of the efficacy and durability in relation to glycemic control in combination with weight loss in most patients. Areas covered: PubMed searches were completed using the terms "GLP-1 receptor agonist", "Liraglutide", "Liraglutide and CVD", "Liraglutide and CVD risk factors". The reference list of articles subsequently identified was searched and arti...
Source: Expert Review of Cardiovascular Therapy - May 7, 2019 Category: Cardiology Tags: Expert Rev Cardiovasc Ther Source Type: research